BTS
ALXN

BB&T Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

BB&T Securities’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$684K Buy
6,993
+173
+3% +$19.5K 0.01% 967
2019
Q2 		$893K Buy
6,820
+561
+9% +$72.3K 0.01% 863
2019
Q1 		$846K Buy
6,259
+2,313
+59% +$288K 0.01% 871
2018
Q4 		$384K Sell
3,946
-684
-15% -$80.9K ﹤0.01% 1082
2018
Q3 		$643K Buy
4,630
+587
+15% +$73.6K 0.01% 977
2018
Q2 		$501K Buy
4,043
+404
+11% +$47.2K 0.01% 1080
2018
Q1 		$405K Buy
3,639
+248
+7% +$29.6K ﹤0.01% 1110
2017
Q4 		$405K Buy
3,391
+10
+0.3% +$1.22K 0.01% 1070
2017
Q3 		$474K Buy
3,381
+227
+7% +$30.8K 0.01% 988
2017
Q2 		$383K Sell
3,154
-4,279
-58% -$498K 0.01% 1061
2017
Q1 		$901K Sell
7,433
-4,501
-38% -$580K 0.01% 684
2016
Q4 		$1.46M Hold
11,934
– – 0.02% 519
2016
Q3 		$1.46M Buy
11,934
+3,402
+40% +$438K 0.02% 514
2016
Q2 		$996K Buy
8,532
+2,278
+36% +$323K 0.02% 602
2016
Q1 		$870K Buy
6,254
+438
+8% +$64.3K 0.01% 616
2015
Q4 		$1.11M Buy
5,816
+1,060
+22% +$185K 0.02% 503
2015
Q3 		$743K Buy
4,756
+690
+17% +$126K 0.02% 588
2015
Q2 		$735K Buy
4,066
+2,351
+137% +$406K 0.02% 615
2015
Q1 		$297K Buy
1,715
+311
+22% +$56.3K 0.01% 883
2014
Q4 		$260K Buy
+1,404
New +$260K 0.01% 937
2014
Q1 		– Sell
-1,609
Closed -$214K – 978
2013
Q4 		$214K Buy
+1,609
New +$193K 0.01% 823

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BB&T Securities's ALXN Position: Q3 2019 in Review

BB&T Securities increased its Alexion Pharmaceuticals (ALXN) stake by 2.5% in Q3 2019, buying an estimated $19.5K and bringing the position to 6,993 shares worth $684K. The position accounts for 0.01% of the portfolio, ranked #967.

BB&T Securities first reported a position in ALXN in Q4 2013 and has held it in 21 quarters since. The position peaked at $1.46M in Q4 2016. 648 funds tracked by Wall St. Rank hold ALXN as of Q3 2019.

  • BB&T Securities held 6,993 shares of Alexion Pharmaceuticals worth $684K as of Q3 2019.
  • BB&T Securities bought 173 Alexion Pharmaceuticals shares in Q3 2019, an estimated $19.5K.
  • Alexion Pharmaceuticals made up 0.01% of BB&T Securities's portfolio in Q3 2019, its #967 holding.
  • BB&T Securities first reported a position in Alexion Pharmaceuticals in Q4 2013 and has held it in 21 quarters since.
  • BB&T Securities's Alexion Pharmaceuticals position peaked at $1.46M in Q4 2016.
  • 648 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2019.

Based on BB&T Securities's 13F filing for Q3 2019, filed 30 Oct 2019.